Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intercept

- PMLiVE

Gilead expands liver disease pipeline with $4.3bn CymaBay acquisition

The deal gives the company access to a candidate being evaluated in primary biliary cholangitis

- PMLiVE

Boehringer Ingelheim and Ribo announce liver disease partnership worth over $2bn

More than 440 million people worldwide are estimated to live with the inflammatory liver disease NASH

- PMLiVE

Honoring Educational Partners at ACG

The recent ACG conference was an opportunity for members of the Medscape team to shine a light on their educational partners and honor them for their exceptional work.On October 21,...

Medscape Education Global

- PMLiVE

Gilead’s Veklury recommended by CHMP for COVID-19 in patients with hepatic impairment

If approved, Veklury would become the first COVID-19 antiviral authorised for use across all stages of liver disease

International NASH Day 2023

Shari Dermer, PhD of Medscape Education, hosted Michael Betel, Founder and President of Fatty Liver Alliance, in an engaging conversation around the importance of NASH awareness, diagnosis, and prognosis. Listen...

Medscape Education Global

- PMLiVE

Ipsen to acquire rare disease specialist Albireo in deal worth over $950m

The deal will strengthen the biopharma’s liver disease pipeline with the addition of Bylvay

- PMLiVE

How the WHO hepatitis strategy measures up in the field

With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination...

Avalere Health

- PMLiVE

Gilead and Novo Nordisk boost NASH partnership with new mid-stage study

The two companies first announced their NASH collaboration in 2019

Podcast

Living With Chronic Illness (Series one)

Research Partnership

- PMLiVE

Merck enters agreement with Hanmi for investigational NASH drug

Licensing agreement includes $10m upfront payment

- PMLiVE

Genfit scraps phase 3 trial of experimental NASH drug

Drug failed to meet primary endpoint in interim analysis

- PMLiVE

Zydus Cadila scores first ever NASH approval, in India

Drug has already been approved for diabetes related conditions

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links